Medicare Rx Coverage Rules Could Compromise Beneficiary Safety – Blues Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Some drug classes with a two-drug coverage requirement could force plans to cover a product they consider to be less safe than another in the class, Excellus BlueCross BlueShield exec says. An internal analysis finds drug costs will rise at least 3.5% if U.S. Pharmacopeia’s “recommended subdivisions” are turned into classes.
You may also be interested in...
Medicare Rx Plans Need Six Months To Review New Drugs, Blues Say
Draft formulary guidelines’ requirement that plans make a coverage decision for new chemical entities within 90 days is too short, Horizon Blue Cross Blue Shield exec tells CMS. Independence Blue Cross exec says longer review period will help ensure drug safety in light of faster FDA review times.
Medicare Rx Plans Need Six Months To Review New Drugs, Blues Say
Draft formulary guidelines’ requirement that plans make a coverage decision for new chemical entities within 90 days is too short, Horizon Blue Cross Blue Shield exec tells CMS. Independence Blue Cross exec says longer review period will help ensure drug safety in light of faster FDA review times.
CMS Finalizing Plans For Medicare Rx Regions, Formulary Standards
Agency is expected to publish documents defining regional maps for Medicare Rx and standards for review of Medicare formularies in the next two weeks – and potentially by Dec. 3.